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The carbohydrate moieties present on membrane-bound glycoproteins have
been implicated in a variety of cellular functions including protection from
intracellular degradation, stabilization of protein conformation and assembly of
oligomeric structures, sorting of proteins within the cell from those destined to
be exported (secreted or membrane bound), binding sites for intercellular
interactions, and determinants ofimmunological specificity (see references I and
2 for review). The contribution of glycan moieties to any of these functions can
vary widely for different glycoproteins, with no general consensus evident.
Studies investigating the functional role of carbohydrates on cell surface
proteins have been based on methods that eliminate or alter glycan moieties.
These methods include the generation ofglycosylation-deficient mutant cells (3),
treatment with inhibitors of glycosylation such as tunicamycin (4), or sugar
analogs (5), andtreatment with chemicals or glycosidases(5, 6). Thedisadvantage
of these nonspecific approaches, especially in the study of intercellular interac-
tions, isthat allcell-surface glycoproteinsare affected. This global deglycosylation
can result in a large increase in the net hydrophobicity and disorganization of
the membrane environment. Furthermore, the majority of these methods are
usuallyincomplete and have inhibitory or cytotoxic effectson thecells. Therefore
it is not surprising that conflicting reports have been published describing the
importance ofglycosylation on the expression and function ofvarious membrane
proteins (1, 2).
One family of cell surface glycoproteins expressed on all nucleated cells is the
major histocompatibility complex class I antigens (7). MHC class I molecules play
an important role in immunologic recognition and can function as target mole-
cules for allospecific cytotoxic T lymphocytes (CTL). Class I HLA molecules are
heterodimers consisting of a highly polymorphic, glycosylated transmembrane
heavy chain of -44 kD, noncovalently associated with 02-microglobulin AM), '
an invariant, nonglycosylated polypeptide of 11.5 kD. Determinants recognized
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FIGURE 1 . Schematic dia-
gram of N-linked glycosyla-
tion sites on human HLA and
mouse H-2 class I antigens.
by T cells appear to map to the first two external globular domains of the HLA
heavy chain, those that show the greatest amino acid variation (8-13). Carbohy-
drate moietiesare also present in these segments, N-linked toasparagine residues
at position 86 on all human HLA antigens, and at positions 86 and 176 on all
murine H-2 antigens (see Fig. 1). An additional glycan is present at residue 256
on murine H-2Kd, Db, and Ld antigens (11).
Glycosidases and inhibitors of glycosylation have been used to investigate the
biosynthesis of class I HLA and 02m molecules (14, 15). In the presence of
tunicamycin, chain association occurs at about the same rate as in its absence,
and the deglycosylated class I complex reportedly reaches the surface atthe same
rateas normal glycosylated molecules, without a noticeable difference in proteo-
lytic degradation. Furthermore, most serologic determinants remain intact (14,
16). However, the role of the class 1 oligosaccharide in the recognition of the
molecule by allogeneic or virus-specific HLA-restricted CTL remains unclear.
Although no data is available in humans, modification of the carbohydrate on
intact stimulator or target cells in mice has been observed to inhibit (17-19),
stimulate (20, 21), or have no effect (19, 22, 23) on T cell responses. Recently,
Goldstein and Mescher (24) using liposomes carrying murine H-2Kk antigensAsn
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devoid of carbohydrates, suggested that the glycans on MHC class I molecules
are not required to trigger the maturation of precursor to effector CTL.
Here we have taken another approach in which we tailor altered HLA proteins
at the DNA level by eliminating or creating the recognition signal for N-linked
glycosylation, (Asn-X-Ser/Thr), using oligonucleotide-directed mutagenesis, and
analyze the expression, conformation, and functional recognition of these mutant
HLA molecules after gene transfer into appropriate recipient cells.
Materials and Methods
Oligonucleotide-directed Mutagenesis. Synthetic oligonucleotides were synthesized by
the solid-phase phosphotriester method (25) using an automated synthesizer (Applied
Biosystems, Foster City, CA), purified through 20% polyacrylamide gel electrophoresis,
and 5'-phosphorylated using T4 polynucleotide kinase. The oligonucleotides used in this
study are listed in Table I. Site-specific mutagenesis was performed on double-stranded
DNA plasmids using the protocol outlined in Fig. 2. Supercoiled plasmid DNA purified
from a cesium chloride gradient was digested separately in two reactions using one (to
linearize the plasmid in the vector sequence) and two (to gap the region in the HLA
sequence to be mutated) restriction enzymes, respectively. The resultant molecules were
mixed in equimolar ratio, denatured by boiling, and renatured with the oligonucleotide
at molar ratios of 1 :20 or 1 :200 pmol at 10°C below its calculated disassociation temper-
ature [melting temperature, Tm = 4°(G + C) + 2 °(A + T)]) for 2 h. After cooling the
reaction on ice, the single-stranded gap was filled by primer extension and the plasmid
was covalently closed by adding 0.5 mM deoxynucleotides, Escherichia coli DNA polym-
erase I Klenow fragment, and T4 DNA ligase at 15'C for at least 20 h, as recommended
by Zoller and Smith (26). The ligation mixture was then used to transform competent E.
coli HB 101 . Ampicillin-resistant colonies were transferred to Biotrans nylon membranes
(ICN Biomedicals, Inc., Irving, CA) and the colonies harboring the mutant plasmid were
detected by colony hybridization (27) using the 5' end-labeled oligonucleotide ('y-[a2p]-
ATP; 6,000 Ci/mmol; New England Nuclear, Boston, MA). Hybridization was carried
out at 10°C below the calculated Tm for 12-16 h using 2 x 106 cpm/filter in 6x SSC (lx
SSC is 15 mM NaCI, 15 mM sodium citrate, pH 7.0); 10% Denhardt's solution, and 0.1
SDS followed by increasing temperature washes using 6x SSC and 0.05% sodium pyro-
phosphate. The filters were exposed at -70 ° C to Kodak XAR film with Cronex intensi-
fying screens for 1-3 h.
DNA from positive colonies, isolated from 5 ml cultures (28), was digested with
appropriate restriction enzymes and analyzed by Southern blot hybridization (29) with
the 5' s2P end-labeled oligonucleotide to assure correct localization of the primer to the
appropriate HLA domain. Finally, since primary colonies harbor both strands of DNA
(normal and mutated), retransformation and rescreening by colony hybridization were
First Second Amino acid residues
HLA gene protein protein
domain domain 86 176 178
HLA-B7 + - Asn Lys Lys
B7M86- - - Gin Lys Lys
B7M176` + + Asn Asn Thr
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FIGURE 2.
￿
Schematic diagram for oligonucleotide-directed mutagenesis in double-stranded
plasmid molecules. The recombinant plasmid containing the HLA-B7 gene is digested with
one (Hind Ill) or two (Kpn I and Sma I) restriction enzymes (for mutagenesis in the a-2
domain). The two reactions are mixed with the mismatched oligonucleotide, denatured by
boiling, and reannealed. Only 25% of the resulting molecules are appropriately gapped. The
gap created is then filled by polymerase I (Klenow) in the presence of deoxynucleotides and
the molecule ligated by T4 ligase. The ligated mixture is transformed into E. coli and drug
resistant colonies are screened by colony hybridization using
12P end-labeled oligonucleotide.
Appropriate colonies are further purified and characterized.
performed to obtain purified mutant plasmid DNA. The frequency of generation of the
desired mutation ranged from 1 to 10%, and colonies were usually homogeneous after
the second transformation. All enzymes used were purchased from New England Biolabs
(Beverly, MA) and used as recommended.
Final confirmation of the desired mutation was obtained by DNA sequence analysis
using a modification of the dideoxy chain-termination method (30), after subcloning the
fragments corresponding to the appropriate HLA exon into M13 Mp18 or Mp19 vectors.
Sequencing primers and kit were purchased from New England Biolabs. Sequence
experiments were performed using a-s'S-dATP (500 Ci/mmol; Amersham Corp., Arling-
ton Heights, IL).
Cell Culture and DNA-mediated Gene Transfer.
￿
All monolayer cell lines were maintained
in a-MEM (Gibco, Grand Island, NY), supplemented with 10% heat-inactivated FCS
(HIFCS) (M.A. Bioproducts, Bethesda MD), penicillin/streptomycin, and 2 mM glutamine .
LJ26 (mouse L cells expressing human 02m) (31), was a gift from L. Herzenberg (Stanford
University, Palo Alto, CA). The human rhabdomyosarcoma cell line, RD, was HLA-typed
by M. Pollack (Baylor College of Medicine, Waco, TX) as HLA-AI ;Bw51,B14 (32).
Transfected cell lines were maintained in the appropriate selectable medium as described
(32). Cotransfection (HLA plasmid/selectable marker plasmid mass ratio of 20:1) was
carried out using the recombinant plasmid containing the HLA-B7 gene (p158R1) or the
mutated plasmids B7M86-, B7M176+, or B7M86-/176+, together with the plasmid
containing the Tn5 neomycin resistance gene (pSV2neo) (33). Additional high-molecular-
mass recipient cell DNA was used as carrier. Selection medium containing 0.5-1 mg/ml
G418/geneticin sulfate (Gibco) was added 48-60 h after transfer, and fresh selectionBARBOSA ET AL.
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media was replaced every 2-3 d. Entire flasks of colonies or individual colonies picked
using cloning cylinders were harvested 10-14 d after selection.
MonoclonalAntibodies.
￿
mAb-producing hybridoma cells were grown in BALB/c mouse
ascites. The specificities and reference to the original characterizations of the HLA mAb
have been described (34-37). mAb recognizing monomorphic HLA-A,B,C determinants
were W6/32 and 9 .12 . The panel of allotypic mAb used to characterize mutant HLA-137
gene expression included BB7.1 (HLA-137), ME1 (HLA-137, -1327, -1322), MB40.2 (HLA-
B7, -1140), MB40.3 (HLA-137, -1140), B27M1 (HLA-137, -27). B locus-specific mAb
included 4E and 1 .23. Other mAb that bind to HLA-137 but have a wider reactivity
included BB7.6 and BB7.7. Rabbit anti-heavy chain serum, anti-H, was a gift of Dr.
Hidde Ploegh, Netherlands Cancer Institute (Amsterdam, The Netherlands).
Cell Surface Immunofluorescence and Flow Cytometry.
￿
Cells were detached from mono-
layer culture by using 0.03% EDTA in PBS without calcium or magnesium, and were
washed with media containing 2% filtered HIFCS and 0.02% sodium azide. Standard
indirect immunofluorescence was performed as described (32) on 106 cells/assay with
saturating amounts of antibody in 50 IA1 medium at 4 ° C for 45 min. The cells were washed
twice with media and incubated at 4 ° C for another 45 min with fluorescein isothiocyanate-
conjugated goat F(ab')2 anti-mouse IgG antibody (Cappel Laboratories, Cochranville,
PA) diluted 1 :20. Afterthree washes, the cellswere either fixed in 1 % paraformaldehyde
for analysis or analyzed directly. Evaluation ofimmunofluorescence and sterile cell sorting
was performed on an Epics V system interfaced with a MDADS multichannel analyzer
(Coulter Electronics, Hialeah, FL). Relative linear fluorescence values were calculated
from peak logarithmic channel numbers as described by Muirhead et al. (38), using
polystyrene microspheres of known fluorescence intensities as standards (Coulter Elec-
tronics).
Metabolic Cell Labeling, Immunoprecipitation, and Gradient SDS GelElectrophoresis.
￿
Cells
(2-5 X 106) were labelled by incubation in methionine-free a-MEM containing 10%
HIFCS in the presence of 250 ACi of ["SJmethionine (500 Ci/mol; New England Nuclear)
for 12-16 h at 37 °C. When used, tunicamycin (3 wg/ml) was added to the media 4-6 h
previously, and remained throughout the time of labeling. Labeled cells were removed
from monolayer culture using 0.03% EDTA in PBS and washed twice before lysing in
1 .0 ml of lysis_ buffer (1% NP-40, 10 mM Tris-HCI, pH 7 .5, 1 MM MgC12, and 0 .1 mM
PMSF) on ice for 30 min. The lysates were centrifuged for 10 min in an Eppendorf
centrifuge to remove nuclei, and the supernatants were used immediately or stored at
-70'C. Preclearing and immunoprecipitation with specific mAb was carried out as
described (15), and the immune complexes were precipitated with protein A-Sepharose
beads (Pharmacia Fine Chemicals, Piscataway, NJ), followed by extensive washes. The
samples were boiled in elution buffer containing SDS and 2-ME and analyzed by electro-
phoresis on a 7-15% linear gradient SDS-polyacrylamide gel followed by fluorography
and drying for exposure at -7 ° C to Kodak XAR-5 X-ray film.
Generation of Human Alloreactive CTL Clones and Cytotoxicity Assays.
￿
Isolation and
culture of CTL clones used in this study have been described elsewhere (39). CTL clones
were isolated from a single volunteer (HLA-A11,Aw32; B27,Bw51 ; Cw2; DR7). Isolated
mononuclear cells at 2 X 106 cells/ml were stimulated in culture with 105 cells/ml
irradiated JY lymphoblastoid cells (HLA-A1,-B7 ; DR4.6), or murine L cell transfectants
expressing HLA-137 antigens, in 2 ml wells (Linbro, McLean, VA)-at 37 ° C. Bulk cultures
were maintained by stimulation with irradiated JY cells every 1-2 wk, and stringently
cloned after 6 wk in culture by limiting dilution in 96-well round-bottom microtiter plates
(Linbro) using irradiated JY cells as a feeder layer. RPMI 1640 medium (Gibco) was
supplemented with 10% HIFCS, 5 X 10-'M 2-ME, 10 mM Hepes, penicillin/streptomycin,
and 10% IL-2 conditioned supernatants from PHA and MLC-activated PBL. Clone
specificity was determined by a panel of HLA-typed human lymphoid lines and mAb
blocking.
"Cr-release assays were performed as described (40). Target cells were labeled over-
night as monolayers using 0.1 mCi "Cr (Na25'CrO,; New England Nuclear) in 1 .8 ml
complete media at 37°C. Labelled cells were detached with EDTA and were washed1334 GLYCOSYLATION PLAYS A MINIMAL ROLE IN HLA RECOGNITION
threetimes. CTL-mediated lysisassays wereperformed intriplicate in V-bottommicrotiter
wells (Linbro). Effectors were added in threefold dilutions to 10' target cells/well.
Microtiter plates were centrifuged and incubated at 37°C for 4 h before being recentri-
fuged, and the supernatants were assayed for "Cr release. Specific cytotoxicity was
calculated as percent cytotoxicity = 100 x [(experimental release) - (spontaneous re-
lease)]/[(total release) - (spontaneousrelease)]. When blocking with mAbwere used, they
were added at the start of the assay. Standard deviation of the triplicate wells rarely
exceeded 2-4% ofthespecific lysis.
Results
Creation of Glycosylation Mutants in the HLA-B7 Molecule by Oligonucleotide-
directed Mutagenesis. Two oligonucleotide sequences were synthesized (see Ta-
ble I) and used in a modification of standard oligonucleotide-directed mutagen-
esis techniques (see Materials and Methods and Fig. 2) to create the novel HLA-
B7 mutant molecules described in Table I. A 21-mer oligonucleotide containing
two mismatches compared with the HLA-B7 genomic sequence was designed to
create the specific amino acid substitution ofglutamine forasparagine at position
86. This conservative amino acid substitution destroys the recognition sequence
for N-linked glycosylation in the first external domain. A second 20-mer oligo-
nucleotide also containing two mismatches compared with the HLA-B7 genomic
sequence was designed to create the specific amino acid substitutions ofaspara-
gine for lysine at position 178, thus replacing two highly charged amino acids
and creating a recognition sequence for N-linked glycosylation at amino acid
position 176 in the second external domain .
After mutagenesis, ampicillin-resistant colonies harboring the mutated plasmid
were detected by colony hybridization using the appropriate 5' 32P-labeled
oligonucleotide under differential washing conditions (Fig. 3). Plasmid DNA
isolated from positive colonies was digested with several diagnostic restriction
enzymes. The site mutated by the oligonucleotide was confirmed by Southern
blot transfer and hybridization of the filters using the appropriate end-labelled
oligonucleotide followed by differential temperature washes (data not shown).
The vast majority of mutants analyzed hybridized to the restriction fragment
encompassing the appropriate annealing site. DNA fragments, corresponding to
the exons open to the mutagenesis procedure, were isolatedfrompurified mutant
plasmid DNA and subcloned into M13 for DNA sequence analysis. Complete
sequencing of these regions confirmed that the appropriate base changes were
introduced in the sites 86 and 176, corresponding to the sequence of the
oligonucleotide used (Fig. 4). No further base changes were present in the
remaining exon sequences.
Afurther HLA-B7 mutant was constructed lacking the glycosylation site at 86
but containing one at 176 by subsequently mutating the HLA-B7M86" mutant
with the oligonucleotide 176. Colony and Southern blot hybridizations, and
DNA sequence analysis (Fig. 4) confirmed both mutations. An equivalent mutant
B7 molecule was also constructed by exchanging the mutated a-2 domain of
HLA-137M 176+ with the normal a-2 domain of HLA-871486- using Sma I-Kpn
I restriction sites (data not shown).
Surface Expression and mAb Epitope Mapping ofGlycosylation Mutants B7M86-
and B7M176+ in Mouse and Human Cells.
￿
Intracellular processing and surfaceBARBOSA ET AL .
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FIGURE 3 .
￿
Differential colony hybridization screening . DNA from colonies transferred and
grown on nylon membranes was hybridized with the appropriate '2P end-labeled mutagenic
oligonucleotide. Colonies containing mutant plasmid DNA were detected by increasing tem-
perature washes, followed by autoradiography . Examples of both B7M86- and B7M176+ are
shown . RT refers to room temperature wash, and p328, pB7, and pA2 refer to control
colonies containing the vector only, HLA-B7 and HLA-A2 genes, respectively.
expression of the native and mutant HLA-B7 molecules were studied using
DNA-mediated gene transfer . TheHLA genes were cotransferred with pSV2neo
into thehuman rhabdomyosarcoma cell line (RD), as well as mouse L cells (LTK),
and mouse L cells expressing human ,62m (LJ26) . Stable G418-resistant colonies
taken as a mass population were expanded and analyzed for HLA-B7 surface
expression by indirect immunofluorescence (IIF) and flow cytometry using a
panel of HLA-B7-reactive monomorphic and polymorphic mAb (Table II) . Fig.
5 shows the binding of mAb ME1 to the surface of normal HLA-B7, B7M86-,
and B7M176' transfected cells in G418-resistant mass populations derived from
the three recipient lines.
Native HLA-B7 molecules were easily detected on the surface of each human
and murine cell line . In contrast, the substitution of glutamine for asparagine at
residue 86 had a dramatic effect on the surface expression of the mutated HLA-
B7 molecule . No surface expression of B7M86- was detected on mouse L cells
by any of the mAb used . When the B7M86- mutant gene was introduced into
human RD or mouse L cells expressing human 02m, a markedly decreased level
of expression, 50-fold less than that of the normal HLA-B7 gene product, could
be detected by all mAb. Therefore, the reduction or absence of expression was1336 GLYCOSYLATION PLAYS A MINIMAL ROLE IN HLA RECOGNITION
FIGURE 4.
￿
DNAsequence analysis of the glycosylation mutants . Dideoxy chain termination
sequencing was performed after subcloning theDNA fragment corresponding to the appro-
priate HLA exon into M13 MP 18 or MP 19 vectors. Autoradiography of 8% polyacrylamide
gels comparing the sequence of the mutants and wild type DNA around the region of the
mutation is shown . Arrows indicate the corresponding base differences between the mutants
and original HLA-B7 molecule . No other base changes were present throughout the entire
exon .
not due to the alteration of any one epitope . A similar low level of surface
B7M86- antigens could be induced on mouseL cells after treatment with mouse
IFN-y (data not shown) . Three independent clones of mutant B7M86- DNA
were purified, and each displayed identical results after gene transfer (data not
shown) . This, together with the complete sequencing of the region open to
mutagenesis, eliminates the possibility that an additional alteration was inadvert-
ently introduced elsewhere in theHLA gene during the mutagenesis procedure .
After metabolic labelling with [s5S]methionine and subsequent immunoprecip-
itation, the normal HLA-B7 44 kD band was easily detected in HLA-B7 trans-
fectants with mAb ME1 I (Fig. 6) . The presence of the appropriate 40 kD
nonglycosylated heavy chain in the cytoplasm of B7M86- transfectants was
detected but at a lower intensity. Further studies have shown that larger quan-
tities ofB7M86- can be detected in transfectants using a rabbit anti-heavy chain
serum, anti-H, which detects denatured heavy chains not in association with 02m3
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FIGURE 5.
￿
Surface expression of HLA-117, B7M86-, and B7M176' on mouse LTK, mouse
LJ26, and human RD cells. Each histogram represents flow-cytometric analysis of a mixed
population of >100 G418-resistant colonies stained by IIFusing the117-reactive mAb ME1 or
normal mouse serum control (C). Fluorescent signals converted to logarithmic values are
displayedon a 256 multichannel analyzer.
(49 and Barbosa et al ., unpublished results). Tunicamycin treatment produced
the appropriate shift in the size of the normal HLA-117 molecule to 40 kD while
the mutant B7M86- remained unaltered.
In contrast to mutant B7M86-, mouse and human recipient cells transfected
with B7M176+ displayed equivalent levels of surface expression as normal HLA-
B7 (Fig. 5 and Table II). This was true for 10 of 12 mAb analyzed. The binding
of two mAb (MB40.2 and MB40.3), each specific for epitopes common to the
HLA-117 and -1140 molecules, was completely eliminated by the creation of the
glycosylation site at site 176 (Fig. 7). Identical results were seen in transfectants
of all three mouse and human recipient lines analyzed. These two mAb are
thought to recognize spatially separate epitopes on the HLA-B7/1140 molecules,
as suggested by competitive binding experiments (41-43) and differential reac-
tion with the cell line Sweig, which expresses a variant HLA-1140 antigen.
LJ26 and RD transfectants were treated for 48 h with 100 U/ml of mouse or
human IFN-y, respectively. Normal HLA-117, mutant B7M86-, and mutant
B7M176+ transfectants all showed a similar 8-10-fold induction of surface
expression . Lack of binding of MB40.2 or MB40 .3 to B7M176+ transfectants
persisted.
Metabolic labelling with [35S]methionine and subsequent immunoprecipitation
with both rabbit anti-H sera (data not shown) and mAbs W6/32 or ME1
demonstrated equivalent quantities of the appropriate 48 kD dual glycan-
containing heavy chain in the cytoplasm of B7M176+ transfectants as that seen
for the normal 44 kD single glycan-containing chain in HLA-117 transfectants
(Fig. 6). Tunicamycin treatment produced the appropriate shift in B7M176+W m
Z
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V
FIGURE 6 .
￿
[s5S]Methionine labeling andimmunoprecipitation analysis confirms the presence
of appropriate molecule mass changes in mutant HLA-B7 molecules . Normal mouse serum
control (C) and mAb ME 1 (M) precipitates of tunicamycin treated (+) andnontreated (-) cells
were analyzed by a 7.5-15% gradient SDS-polyacrylamide gel . Normal HLA-B7 was precipi-
tated from both the human lymphoblastoid cell JY and HLA-B7-transfected RD cells, while
B7M86- and 137M 176' antigens were precipitated from appropriately transfected RD popu-
lations.
RELATIVE FLUORESCENCE
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FIGURE 7 .
￿
mAb MB40.2 and MB40.3 do not
bind to B7M176+ antigens. RD transfectant
populations expressing homogenous and equiv-
alent levels of HLA-B7 and B7M176+ antigens
were derived by FACS after IIF staining with
mAb ME1 . These FACS-derived sublines were
analyzed for surface expression using mAbs
ME1, MB40 .2, MB40.3 and control (C) stain-
ing. Identical results were obtained for sorted
and nonsorted LTK and LJ26-transfectant
populations.
molecules to the 49 kD band (Fig . 6; incomplete inhibition reveals the 44 kD
single glycan-containing molecule also) .
Tunicamycin Treatment Does Not Rescue the Expression ofB7M86-Antigens to the
Cell Surface nor Allow MB40.2 or MB40.3 mAb to Bind B7M176' Mutant Anti-1340 GLYCOSYLATION PLAYS A MINIMAL ROLE IN HLA RECOGNITION
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FIGURE 8. Tunicamycin treatment did not
rescue expression of B7M86- antigens to the
surface or unmask MB40.2 .or MB40.3 binding
to B7M 176+ mutant antigens. LJ26 clonal
transfectants expressing B7, B7M86-, and
B7M176+ respectively were treated overnight
with 3 wg/ml tunicamycin and harvested alone
with nontreated duplicates for IIF and flow-
cytometry analysis using mAb ME1, MB40.2,
and MB40.3 (identical results as MB40.2). Rep-
licate flasks harvested for immunoprecipitation
indicated that tunicamycin treatment was
~90% complete under the conditions used.
Identical results were obtained with the LTK
(e.g., B7M86- transfectants remained com-
pletely negative) and RD transfectant cell lines.
gens.
￿
The reduced surface expression observed for mutant B7M86- unglyco-
sylated antigens contradicts previous data obtained using the glycosylation inhib-
itor, tunicamycin (14) . Therefore, tunicamycin experiments were initiated to
address whether tunicamycin could have a second unknown effect allowing
transport of deglycosylated HLA antigens to the cell surface, or whether the
nonglycosylated B7M86- heavy chains might be unable to compete with endog-
enous glycosylated HLA or H-2 chains for association with either mouse of
human a2m. In addition, we wished to determine whether the elimination of
binding of mAbs MB40.2 and MB40.3 to B7M 176' mutant antigens was due to
the presence of the carbohydrate glycan or due to the alteration of two positively
charged amino acids at the 176 and 178 positions.
Clonal populations of LJ26 transfectants expressing B7, B7M86-, and
B7MI76+ antigens, respectively, were treated overnight with 3 yg/ml tunica-
mycin and were harvested along with nontreated duplicates for IIF and flow
cytometry and analysis using mAbs ME I, MB40.2, and MB40 .3. Duplicate flasks
of tunicamycin-treated and -untreated cells were also labelled overnight with
[s5S]methionine and harvested for immunoprecipitation with mAb MEI and anti-
H serum to monitor the extent of deglycosylation by tunicamycin. Tunicamycin
treatment was ^-90% complete under the conditions used (data not shown) .
Results shown in Fig. 8A confirm that deglycosylated normal HLA-B7 antigens
are fully capable of reaching the cell surface. Small decreases in expression levelswsaz J5L 4"* '""
IIM10-6 Fluorwe~na
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FIGURE 9.
￿
Creation of an N-linked glycan at
residue 176 incompletely rescues B7M86- mol-
ecules to thecell surface.IIF and FACS analysis
using mAbs W6/32 and MB40.3 of mass pop-
ulation transfected with equivalent amounts of
HLA-B7, B7M86-, B7M86-/176 plasmid
DNA. Relative fluorescence displayedon alog-
arithmic scale.
are likely due to a general inhibitory effect of tunicamycin on protein synthesis
at the concentrations needed for nearly complete inhibition. Tunicamycin treat-
ment, however, was not able to rescue expression of B7M86- antigens to the cell
surface (Fig. 8B). In addition, mAbs MB40.2 and MB40 .3 did not bind to
B7M 176+ mutant antigens after tunicamycin treatment that would have elimi-
nated the glycan moieties on the majority of B7M176+ antigens (Fig. 8C).
Identical results were obtained with LTK and RD transfectant cell lines (data
not shown). Thus, the reduction or lack ofsurface expression of mutant B7M86-
antigens is not due to either cell type or to competition with endogenous
glycosylated HLA or H-2 antigens, and is more likely due to conformational
alterations created by the amino acid change at position 86 . Second, the loss of
binding to B7M176+ mutant antigens by mAb MB40 .2 and MB40 .3 is not due
to the presence of the carbohydrate specifically, but most likely due to confor-
mational alterations either at that site or at another site affected by the replace-
ment of two lysines at positions 176 and 178.
Creation of a Glycan Moiety in the Second Domain Partially Rescues Surface
Expression of B7M86- Unglycosylated Mutant Molecules. The B7M86- mutant
molecule was further mutated by the oligonucleotide 176 to address whether
the presence of a glycan moiety at another location could provide a function
necessary to rescue surface expression. As seen in Fig. 9, mutant B7M86-/176+
showed two- to three-fold increased levels of surface expression over those seen
by mutant B7M86-. These levels were still quite low as compared to normal
HLA-B7. Similar results were observed in LTK and RD transfectants, as well as
for a similar mutant created by an exon swap between mutants B7M86- and
B7M 176' (data not shown). mAb MB40.2 and MB40.3 also did not bind
B7M86-/176+ mutant antigens. All other mAb analyzed bound to B7M86-/176'
mutant antigens with levels similar to W632. We suggest that the small two- to
three-fold increase in expression of B7M86-/176' as compared with B7M86-1342 GLYCOSYLATION PLAYS A MINIMAL ROLE IN HLA RECOGNITION
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FIGURE 10.
￿
Specific lysis of human RD cells expressing transfected HLA-B7 glycosylation
mutants by allospecific CTL. Cloned human RD transfectants expressing HLA-B7 (0),
B7M176+ (p), B7M86- (0), or mock-transfected (*) were used as targets in standard 4-h "Cr-
release assay with human allospecific CTL clones generated as described in Materials and
Methods. RDB7 and RDB7M176+ expressed nearly identical surface antigen levels while
RDB7M86- expressed -50-fold lower levels. A and C are representative HLA-B7 allospecific
clones, while D is a representative HLA-A2 allospecific clone. B represents a bulk CTL
population stimulated with the human lymphoblastoid cell line JY and shows both HLA-A2
and -B7 specificity.
may be due to small structural changes that counteract those created by mutant
B7M86- and not specifically due to the presence or absence of a glycan moiety .
Allospecic CTL Recognition of BMW and B7M176+ Glycosylation Mutants.
Human CTL clones allospecific for HLA-B7 antigens have been generated to
analyze the recognition and lysis of mouse and human target cells expressing
transfected HLA-B7 gene products (32, 39, 40). Only a few of the clones isolated
were capable of lysing mouse cell as well as human cell transfectants, while the
vast majority were capable of only lysing human or monkey cell transfectants
expressing HLA-B7 antigens.
To assess whether the recognition of HLA-B7 was affected by the absence of
glycosylation or the presence of an additional glycan in the second protein
domain, cloned human RD transfectants expressing B7, B7M 176+, and B7M86-
surface antigens were used as targets for various HLA-B7 specific CTL. Repre-
sentative results are shown in Fig. 10 . RD7B7 and RDB7M176+ expressed nearly
identical surface antigen levels, while RDB7M86- expressed ^-50-fold lower
levels of antigen. CTL clones 303 and PT8 lysed RDB7 and RDB7M176+ cells
nearly equivalently. RDB7M86- target cells were lysed also, although less effec-
tively. Similar results were obtained repeatedly and are representative ofall CTL
analyzed. Moreover, a bulk population of CTL stimulated with the humand a e
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FIGURE 11.
￿
Specific lysis of mouse LTK cells expressing transfected HLA-B7 glycosylation
mutants. Cloned mouse LTKtransfectantsexpressing high (0)and low (0)levels of HLA-B7,
and high (*)and low (O) levels of B7M176' were used as targets in standard 4-h "Cr-release
assay using representative B7 allospecific CTL clones previously shown capable of lysing
murine transfectants expressing HLA-B7 (CTL clone 147) or CTL clones incapable of lysing
mouse cell transfectants expressing HLA-B7 (CTL clone 304). High B7 and B7M176'
expressors were equivalent and expressed approximately three times higher levels than
equivalent B7 and B7M776' low-level expressors. Mock transfectant (X) was not lysed by
either clone.
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FIGURE 12 .
￿
Specific lysis of murine LJ26 cellsexpressing human 02m and transfected HLA-
B7 glycosylation mutants. Cloned murine LJ26 transfectants expressing equivalent levels of
HLA-B7 (*), and B7M176'("), and 50-fold lower levels of B7M86- (O), were used as targets
in standard 4-h "Cr-release assayusingrepresentative B7 allospecific CTLclone 147 andCTL
clone 303, and HLA-A2- and -B7-specific bulk CTL. Human lymphoblastoid cell line JY
(HLA-A2, B7 homozygous) (0)waslysedefficiently by allCTL, whileamock LJ26 transfectant
(X), was not lysed by any CTL. OtherCTL clones such as 390, 398, and 399 showed similar
lack of lysis of LJ26 transfectants.
lymphoblastoid cell line JY lysed all three transfectants equivalently. An HLA-
A2-specific CTL clone was unable to recognize and lyse any of the tranfectants.
Because the level ofexpression ofB7M86- antigens is 50-fold lower than HLA-
B7 levels, 10-fold higher levels of B7M86- antigens were induced by human
IFN-7. These cells could be lysed with similar efficiencies as those seen with
untreated RDB7 transfectants (data not shown). Thus, neither mutant dramati-
cally affected recognition by the CTL clones analyzed, and analysis of B7M86-
transfectants served to demonstrate the low threshold of surface HLA required
for recognition and lysis on human cell transfectants.
CTL lysis of LTK and LJ26 transfectants expressing equivalent surface levels
ofHLA-B7 or B7M176+ antigens is shown in Figs. 11 and 12, respectively. CTL
clone 147 is a high-affinity CTL clone previously shown capable oflysing murine
transfectants expressing HLA-B7 (39). Clones 303 and 304 represent the major-
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ity of CTL that are unable to lyse mouse cell transfectants expressing HLA-B7.
Similar results were obtained for CTL clone 147 as was observed on human RD
transfectants. LTK or LJ26 transfectants expressing B7M176+ antigens were
lysed as well as HLA-B7 transfectants. LJB7M86- (Fig. 12) expressed -50-fold
lower levels of B7M86- antigens as determined by IIF and flow cytometry
analysis. LJB7M86- was lysed, but with a lower efficiency. LTKB7M86- showed
no detectable surface expression of B7M86- (but low levels were inducible by
IFN), and was not lysed above background. CTL clones like 303 and 304
remained unable to lyse mouse LTK or LJ26 transfectants expressing any ofthe
HLA-B7 antigens. Thus, the presence of an additional glycan at amino acid
position 176, as seen in all murine H-2 antigens, did not rescue murine transfec-
tants from the species restriction previously observed for the majority ofhuman
allospecific CTL clones isolated.
Discussion
To study the structure/function relationship ofMHCclass I antigens, standard
oligonucleotide-directed mutagenesis procedures (26, 44) have been modified to
develop a relatively simple and efficientprotocol, makingprecise changesdirectly
in double-stranded plasmids in which only a small single-stranded region of the
DNA is accessible to the mutagenicoligonucleotide (Fig. 2). This protocol should
reduce random errors introduced by polymerase I activity and the amount of
DNA sequencing necessary to characterize the mutant. Combined with recent
improvements for DNA sequencing in double-stranded vectors (45), M13 steps
may be eliminated entirely.
Here, HLA-B7 proteins have been altered at the DNA level by either elimi-
nating or creating a recognition signal for N-linked glycosylation, (Asn-X-
Ser/Thr), to address the role of the glycan moiety in protein conformation,
surface expression, and recognition of the molecule by mAb and allospecific
CTL. Using twooligonucleotides, a set offour HLA-B7 moleculeswere analyzed
that had N-linked glycans present or absent at those sites that are highly
conserved in HLA and H-2 class I antigens (Fig. 1). Gene transfer of the mutant
HLA-B7 molecules into human and mouse cell lines demonstrated that the
presence or absence of a carbohydrate moiety at these amino acid positions had
little or no effect on the recognition ofthe HLA-B7 molecule by available mAb
or allospecific CTL.
This work is in strong agreement with recent studies by Shiroshi et al. (46),
Miyazaki et al. (47), and Goldstein and Mescher (24) using similar or different
approaches for murine H-2 antigens. Together, these studies confirm the lack
ofeffect ofdeglycosylation on serologic recognition after tunicamycin treatment
(14), and may help clarify studies using inhibitors of glycosidases to address
carbohydrate's role in Tcell recognition and function (17-23). The preservation
of antigenicity after the removal of glycan moieties in both HLA and H-2
antigens raises the question as to the biological significance of these highly
conserved structures.
Although an in vitro mutagenesis approach eliminates the technical problems
inherent in using glycosylation inhibitors or glycosidases (global effect on all
glycoproteins, toxicity, incompleteness, etc.), and allows the role of particularBARBOSA ET AL.
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glycosylation sites to be individually addressed, the substitution of different
amino acids in the primary structure of antigens may inadvertently alter the
secondary structure of the molecule. This may be evident in the H-2Ld mutant
lackinga glycan at amino acid86 (46). Four mAbshowed a quantitative reduction
in binding, probably not due to the removal of the carbohydrate moiety itself,
but rather to the substitution of a positively charged lysine for asparagine at
position 86. In the HLA-B7 molecule, a conservative change of glutamine for
asparagine at the same residue 86 site had a drastic effect on surface expression,
while a drastic change replacing two highly charged lysine residues -at positions
176 and 178 had no effect on the level of surface expression. It is ossible that
the asparagine residue at position 86 may be critical for protein conformation
and chain association. Recent crystallographic data on HLA-A2 (48) suggest that
a-1 and a-2 domains have a stronger interaction with 02m than previously
predicted (49).
Quantitative and qualitative differences in #2m expression did influence
whether small amounts ofmutant B7M86- protein could reach the cell surface.
Further, the majority of intracellular B7M86- heavy chains were found in a
denatured unassociated state (data not shown). Because a2m association is known
to be critical for intracellular migration and surface expression ofclass I mole-
cules, it is likely that the low surface expression seen for this mutant is due to
problematic association with #2m. This could be caused by structural alteration
due to either the lack of carbohydrate or the substituted amino acid. However,
further mutational work altering the serine to glycine at position 88 to create a
nonglycosylated molecule in HLA-A2 has suggested that alteration of the con-
served asparagine at residue 86, rather than the lack of a carbohydrate moiety
at this position, is important (50). This interpretation is supported by the lack of
effect of tunicamycin on the expression of class I molecules (14). Despite the
alteration in transport, the B7M86- molecules that reach the cell surface at low
levels in human and mouse cells transfected with human 02m or after IFN-'y
induction are recognized appropriately by mAb and allospecific CTL.
Aftercreating a nonglycosylated H-21Ld molecule, Miyazaki et al. (47) observed
a similar drastic reduction in surface expression while leaving intact all functional
recognition by mAb, allospecific CTL, and vesicular stomatitis virus-specific, H-
2Ld-restricted CTL. They showed that this low expression was not due to
increased degradation or accelerated shedding. Impaired intracellular transport
was suggested. However, rather than an effect on protein conformation and 02m
association, they suggested that the carbohydrate moiety itself may aid specific
transport mechanisms in the cell. We have not directly shown that the nongly-
cosylatedHLA-B7M86-heavychains are notdegraded morerapidly than normal
HLA-B7 molecules. However, intracellular labelling after permeabilization has
demonstrated that denatured HLA-B7M86- mutant heavy chains accumulate
and are sequesteredin an unknown compartment in the cell other than the Golgi
(50, 51).
Recent reports by Guan et al. (52) and Machamer et al. (53) using a similar
mutagenesis approach support the concept ofa required functionofglycosylation
for transport ofcertain molecules to the cell surface (either membrane-bound or
secreted). Their results suggest that a single N-linked oligosaccharide at any one
of a number of positions is sufficient for transport of vesicular stomatitis virus G1346 GLYCOSYLATION PLAYS A MINIMAL ROLE IN HLA RECOGNITION
protein or a recombinant growth hormone molecule to the cell surface. We were
able to rescue some surface expression of the HLA-B7M86- mutant by creating
a single N-linked glycan at residue 176 (see HLA-B7M86-/176'0. Datapresented
elsewhere (50, 51) suggest that, for these HLA molecules, this increase in
expression may be due to improved 02m association caused by a conformational
change rather than due to a transport mechanism dependent on the presence of
a carbohydrate moiety.
Surprisingly, the alteration oftwo highly charged lysines at positions 176 and
178 to create a glycosylation site did not affect the transport or expression of
HLA-B7M176+mutant molecules. Alteration ofsite 176 in H-2Ld, conservatively
inserting a glutamine for asparagine, also did not affect surface expression (47).
The presence ofthecarbohydrate moiety itself atposition 176 on HLA-B7M176+
did not affect the binding ofany mAb analyzed, nor did it affect the recognition
and lysis by allospecific CTL. Furthermore, the presence ofa glycan at residue
176 did not promote the lysis of murine cell transfectants by those allospecific
CTLclones previously shown capable of lysing only human cells transfected with
HLA-137 antigens (32, 39, 40). Further characterization of these CTL clones
suggests that their lower affinity requires greater involvement of accessory cell
interaction molecules, for which murine cells may lack appropriate ligands (39).
Where successful lysis did exist, as in human cells, neither the lack of glycan nor
the presence ofa second glycan significantly affected the blocking oflysis typically
observed by antibodies to these molecules (S. J. Mentzer, unpublished results).
The loss of binding of mAb MB40.2 and MB40.3 to the B7M176'' molecules
was a direct consequence of the amino acid changes at this site either because
the lysine residues at positions 176 and 178 represent the epitope recognized by
these mAb, or because another site is conformationally altered by these changes.
Interestingly, substantial evidence suggests that mAb MB40.2 and MB40.3
recognize different epitopes on the HLA-B7 molecule (41-43). Of the known
sequenced HLA proteins to date, only HLA-137 and HLA-1340, the two antigens
recognized by both of these mAb, are identical in the region of amino acids
175-180. Further oligonucleotide-directed mutagenesis in this region may be
informative.
Summary
We have investigated the role of the carbohydrate moiety on the HLA-137
molecule in mAb and CTL recognition using oligonucleotide-directed mutagen-
esis and gene transfer techniques. A conservative substitution of asparagine to
glutamine at amino acid 86 in HLA-137 was created to abolish the unique
glycosylation site present on all HLA molecules. A second mutant B7 molecule
was made by substituting asparagine-aspartic acid-threonine for the resident
lysine-aspartic acid/lysine tripeptide at amino acids 176-178, thus creating an
N-linked glycan at amino acid 176, which is additionally present on all known
murine H-2 class I antigens. Upon gene transfer into mouse and human cell
recipients, the HLA-B7M176' mutant and normal HLA-137 expressed identical
levels of surface protein. However, the binding of two mAbs (MB40.2 and
MB40.3) thought to recognize different epitopes of the HLA-137 molecule was
completely eliminated. In contrast, the HLA-B7M86- mutant displayed nosurface expression (mouse L cells) or minimal surface expression (human RD
cells or mouse L cells coexpressing human 02 microglobulin [02m]) after indirect
immunofluorescence (IIF) and flow cytometric analysis with a panel of 12 HLA-
B7 mAb reactive with monomorphic and polymorphic determinants. Immuno-
precipitation analysis demonstrated that intracellular denatured mutant protein
was present. Tunicamycin treatment did not rescue the expression of HLA-
B7M86- antigens to the cell surface; while interferon did induce higher levels of
surface expression. Tunicamycin treatment also did not allow binding of the
mAbs MB40.2 or MB40.3 to HLA-B7M176+ mutant antigens, suggesting that
the carbohydrate moiety itself was not directly involved in the recognition or
conformation of these mAb epitopes. Further mutation of the B7M86- molecule
to create a glycan moiety at amino acid position 176 (B7M86-/176+) did not
rescue normal levels of surface expression. Finally, neither mutation was seen to
affect recognition by a panel of 12 allospecific CTL clones. The low expression
of HLA-B7M86` on the surface of human cell transfectants was sufficient to
achieve lysis, albeit at a reduced efficiency, and lysis could be increased by
interferon induction of higher levels of expression. Thus, the carbohydrate
moiety on HLA antigens plays a minimal or nonexistent role in recognition by
available mAb and allospecific CTL clones.
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